Conflitti P, Lyman E, Sansom M, Hildebrand P, Gutierrez-de-Teran H, Carloni P
Nat Rev Drug Discov. 2025; .
PMID: 39747671
DOI: 10.1038/s41573-024-01083-3.
Garcia-Cuesta E, Martinez P, Selvaraju K, Ulltjarn G, Gomez Pozo A, DAgostino G
Elife. 2024; 13.
PMID: 39248648
PMC: 11383527.
DOI: 10.7554/eLife.93968.
Faivre N, Verollet C, Dumas F
Retrovirology. 2024; 21(1):2.
PMID: 38263120
PMC: 10807162.
DOI: 10.1186/s12977-024-00634-1.
Da Silva E, Scott M, Enslen H, Marullo S
Int J Mol Sci. 2023; 24(24).
PMID: 38139265
PMC: 10744302.
DOI: 10.3390/ijms242417438.
Li M, Qing R, Tao F, Xu P, Zhang S
Int J Mol Sci. 2023; 24(22).
PMID: 38003455
PMC: 10671024.
DOI: 10.3390/ijms242216266.
Structural basis of dimerization of chemokine receptors CCR5 and CXCR4.
Di Marino D, Conflitti P, Motta S, Limongelli V
Nat Commun. 2023; 14(1):6439.
PMID: 37833254
PMC: 10575954.
DOI: 10.1038/s41467-023-42082-z.
Multiple mechanisms of self-association of chemokine receptors CXCR4 and CCR5 demonstrated by deep mutagenesis.
Gill K, Mehta K, Heredia J, Krishnamurthy V, Zhang K, Procko E
bioRxiv. 2023; .
PMID: 36993221
PMC: 10055436.
DOI: 10.1101/2023.03.25.534231.
Single-molecule and super-resolved imaging deciphers membrane behavior of onco-immunogenic CCR5.
Hunter P, Payne-Dwyer A, Shaw M, Signoret N, Leake M
iScience. 2022; 25(12):105675.
PMID: 36561885
PMC: 9763858.
DOI: 10.1016/j.isci.2022.105675.
Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5 dynamics depending on its dimerization status.
Momboisse F, Nardi G, Colin P, Hery M, Cordeiro N, Blachier S
Elife. 2022; 11.
PMID: 35866628
PMC: 9307273.
DOI: 10.7554/eLife.76281.
Shifting CCR7 towards Its Monomeric Form Augments CCL19 Binding and Uptake.
Gerken O, Artinger M, Legler D
Cells. 2022; 11(9).
PMID: 35563750
PMC: 9101108.
DOI: 10.3390/cells11091444.
Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies.
Weichseldorfer M, Tagaya Y, Reitz M, DeVico A, Latinovic O
J Transl Med. 2022; 20(1):39.
PMID: 35073923
PMC: 8785515.
DOI: 10.1186/s12967-022-03243-8.
The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer.
Singh K, Nassar N, Bachari A, Schanknecht E, Telukutla S, Zomer R
Cancers (Basel). 2021; 13(16).
PMID: 34439262
PMC: 8392233.
DOI: 10.3390/cancers13164107.
In Silico Identification of Cholesterol Binding Motifs in the Chemokine Receptor CCR3.
van Aalst E, Koneri J, Wylie B
Membranes (Basel). 2021; 11(8).
PMID: 34436333
PMC: 8401243.
DOI: 10.3390/membranes11080570.
Modeling of CCR5 Recognition by HIV-1 gp120: How the Viral Protein Exploits the Conformational Plasticity of the Coreceptor.
Jacquemard C, Koensgen F, Colin P, Lagane B, Kellenberger E
Viruses. 2021; 13(7).
PMID: 34372601
PMC: 8310383.
DOI: 10.3390/v13071395.
Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
Huang B, Wang H, Zheng Y, Li M, Kang G, Barreto-de-Souza V
J Med Chem. 2021; 64(11):7702-7723.
PMID: 34027668
PMC: 10548452.
DOI: 10.1021/acs.jmedchem.1c00408.
Differences in interactions between transmembrane domains tune the activation of metabotropic glutamate receptors.
Thibado J, Tano J, Lee J, Salas-Estrada L, Provasi D, Strauss A
Elife. 2021; 10.
PMID: 33880992
PMC: 8102066.
DOI: 10.7554/eLife.67027.
Interclass GPCR heteromerization affects localization and trafficking.
Toneatti R, Shin J, Shah U, Mayer C, Saunders J, Fribourg M
Sci Signal. 2020; 13(654).
PMID: 33082287
PMC: 7717648.
DOI: 10.1126/scisignal.aaw3122.
Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages.
Aquaro S, Borrajo A, Pellegrino M, Svicher V
Virulence. 2020; 11(1):400-413.
PMID: 32375558
PMC: 7219522.
DOI: 10.1080/21505594.2020.1760443.
Conformational dynamics between transmembrane domains and allosteric modulation of a metabotropic glutamate receptor.
Gutzeit V, Thibado J, Stor D, Zhou Z, Blanchard S, Andersen O
Elife. 2019; 8.
PMID: 31172948
PMC: 6588349.
DOI: 10.7554/eLife.45116.
The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?.
Moreno E, Cavic M, Krivokuca A, Casado V, Canela E
Front Pharmacol. 2019; 10:339.
PMID: 31024307
PMC: 6459931.
DOI: 10.3389/fphar.2019.00339.